1. Home
  2. Projects & results
  3. Project Factsheets
  4. DO->IT

DO->IT

Big data for better outcomes, policy innovation and healthcare system transformation
Closed | IMI2 |
DO-IT logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 7
Grant agreement number
116055

Type of Action: 
CSA (Coordination and Support Action)

Contributions €
IMI Funding
3 549 833
EFPIA in kind
3 604 817
Other
37 105
Total Cost
7 191 755

Summary

Institutions across Europe house rich databases with detailed personal and biological information. If linked, this ‘big data’ has the potential to deliver insights that will allow healthcare systems to ensure that the patient is truly at the centre of decision-making, with outcomes that matter and resources focused on treatments that really make a difference. IMI’s Big Data for Better Outcomes (BD4BO) programme is generating knowledge, data and methodologies needed to support the transition towards more outcomes-focused, sustainable healthcare systems in Europe. Through its projects, the programme focuses on a number of key therapeutic areas, namely Alzheimer’s disease, heart disease, and certain cancers.

The DO>IT project was launched to provide a coordination platform for the BD4BO programme, exploiting synergies across the projects and maximising its impact on healthcare systems. Specially, DO>IT will aggregate learnings and disseminate findings from the projects; develop minimum data privacy standards; engage with key stakeholders; and recommend areas for future collaborative research.

Achievements & News

BD4BO releases toolkit to assist big data projects on outcomes work
July 2018

DO>IT, the coordination project of the Big Data for Better Outcomes (BD4BO) programme, has delivered a toolkit to support the other BD4BO projects in the identification, selection and measurement of outcomes. The BD4BO programme currently has projects focusing on Alzheimer’s disease, blood cancers, prostate cancer, and heart disease. ###The new toolkit represents a practical guide which will help the projects to adopt a standardised approach when developing core outcome sets (COS) in their disease areas. The toolkit proposes six main stages for developing a COS, from scoping to dissemination, with a focus on stakeholder input across all stages to ensure a wide range of perspectives are taken into account. Whilst the toolkit highlights any existing best practice for developing COS, it also presents a range of methodological options which BD4BO projects can consider depending on the scope of the work and resources available. Each stage includes decision-making flowcharts, summaries of key considerations and case studies to highlight the key factors and considerations when developing COS. These typically reflect aspects that are of importance to BD4BO projects around the use of data from a range of sources from ‘real world' settings in addition to clinical trials.

Participants Show participants on map

EFPIA companies
  • Amgen, Brussels, Belgium
  • Asociacion Nacional Empresarial De La Industria Farmaceutica, Madrid, Spain
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
  • Celgene Management SARL, Couvet, Switzerland
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Federation Europeenne D'Associations Et D'Industries Pharmaceutiques, Brussels, Belgium
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Health Iq Limited, London, United Kingdom
  • Institut De Recherches Internationales Servier Iris, Suresnes, France
  • Intersystems GMBH, Darmstadt, Germany
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
  • Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States
  • Novartis Pharma AG, Basel, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • The Association Of The British Pharmaceutical Industry, London, United Kingdom
  • UCB Biopharma SRL, Brussels, Belgium
  • Verband Forschender Arzneimittelhersteller Ev, Berlin, Germany
Universities, research organisations, public bodies, non-profit groups
  • Folkehelseinstituttet, Oslo, Norway
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • London School Of Economics And Political Science, London, United Kingdom
  • National Institute For Health And Care Excellence, Manchester, United Kingdom
  • Semmelweis Egyetem, Budapest, Hungary
  • Statens Legemiddelverk, Oslo, Norway
  • Tandvards-Och Lakemedelsformansverket, Stockholm, Sweden
  • The University Of Liverpool, Liverpool, United Kingdom
  • Tmf - Technologie Und Methodenplattform Fur Die Vernetzte Medizinische Forschung Ev, Berlin, Germany
  • Universita Commerciale Luigi Bocconi, Milan, Italy
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Ihe, Institutet For Halso- Och Sjukvardsekonomi Aktiebolag, Lund, Sweden
Patient organisations
  • European Cancer Patient Coalition, Brussels, Belgium
  • The European Multiple Sclerosis Platform Aisbl, Brussels, Belgium

Project leader
Stephan Korte
Novartis
This project is funded by the Innovative Medicines Initiative, a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA)
www.imi.europa.eu
eu-flagefpia